Baidu
map

PLos One:非小细胞肺癌自适应放疗的放射学方法

2018-11-22 xiangting MedSci原创

根据经验,混合了语义和基于图像特征的放射学特征在非小细胞肺癌的个性化自适应放疗中的结果令人满意。

精准医学的主要目标是尽量减少副作用并优化治疗效果。医学影像技术的最新进展使得更先进的影像分析方法成为现实,而不仅仅是肿瘤大小或放射性示踪剂摄取指标的简单测量。从医学影像中提取定量特征来表征肿瘤病理学或异质性是一个有趣的研究过程,可以为指导治疗和预测生存率提供有用信息。这项研究讨论了支持放疗概念的理论基础,及其在放射肿瘤学研究领域应用于非小细胞肺癌的可行性。共研究了91例III期患者,这些患者在治疗期间如果肿瘤减少同时接受化疗和自适应放疗。考虑了12个统计特征和从CT图像中提取的230个纹理特征。这项研究中,研究人员在开始CT模拟的基础上,使用集成学习方法将患者化放疗期间的数据分为自适应或非自适应组。研究数据支持可以识别具体特征的假说(AUC 0.82)。根据经验,混合了语义和基于图像特征的放射学特征在非小细胞肺癌的个性化自适应放疗中的结果令人满意。原始出处:Sara Ramella. A radiomic approach for adaptive radiotherapy in non-small cell lung cancer patients. PLos One. 21 Nov

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790297, encodeId=7a6b1e9029795, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 11 19:42:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810849, encodeId=65b91810849e5, content=<a href='/topic/show?id=3be0863e175' target=_blank style='color:#2F92EE;'>#自适应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86371, encryptionId=3be0863e175, topicName=自适应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Mar 11 02:42:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059766, encodeId=2a8e2059e666d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat May 18 09:42:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385628, encodeId=6441138562885, content=<a href='/topic/show?id=b3d05e3382b' target=_blank style='color:#2F92EE;'>#放射学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57338, encryptionId=b3d05e3382b, topicName=放射学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3bb506, createdName=kkunny, createdTime=Sat Nov 24 04:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790297, encodeId=7a6b1e9029795, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 11 19:42:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810849, encodeId=65b91810849e5, content=<a href='/topic/show?id=3be0863e175' target=_blank style='color:#2F92EE;'>#自适应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86371, encryptionId=3be0863e175, topicName=自适应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Mar 11 02:42:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059766, encodeId=2a8e2059e666d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat May 18 09:42:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385628, encodeId=6441138562885, content=<a href='/topic/show?id=b3d05e3382b' target=_blank style='color:#2F92EE;'>#放射学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57338, encryptionId=b3d05e3382b, topicName=放射学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3bb506, createdName=kkunny, createdTime=Sat Nov 24 04:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2019-03-11 naiwu77
  3. [GetPortalCommentsPageByObjectIdResponse(id=1790297, encodeId=7a6b1e9029795, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 11 19:42:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810849, encodeId=65b91810849e5, content=<a href='/topic/show?id=3be0863e175' target=_blank style='color:#2F92EE;'>#自适应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86371, encryptionId=3be0863e175, topicName=自适应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Mar 11 02:42:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059766, encodeId=2a8e2059e666d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat May 18 09:42:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385628, encodeId=6441138562885, content=<a href='/topic/show?id=b3d05e3382b' target=_blank style='color:#2F92EE;'>#放射学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57338, encryptionId=b3d05e3382b, topicName=放射学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3bb506, createdName=kkunny, createdTime=Sat Nov 24 04:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1790297, encodeId=7a6b1e9029795, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 11 19:42:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810849, encodeId=65b91810849e5, content=<a href='/topic/show?id=3be0863e175' target=_blank style='color:#2F92EE;'>#自适应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86371, encryptionId=3be0863e175, topicName=自适应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Mar 11 02:42:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059766, encodeId=2a8e2059e666d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat May 18 09:42:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385628, encodeId=6441138562885, content=<a href='/topic/show?id=b3d05e3382b' target=_blank style='color:#2F92EE;'>#放射学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57338, encryptionId=b3d05e3382b, topicName=放射学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3bb506, createdName=kkunny, createdTime=Sat Nov 24 04:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-24 kkunny

相关资讯

Sci Rep:醉茄素A抑制非小细胞肺癌上皮细胞向间充质细胞的转化

这项研究提供了额外的证据,表明WFA对NSCLC细胞EMT诱导的抑制作用,并进一步证明了WFA对NSCLC转移的治疗潜力。

CLIN CANCER RES:Abemaciclib联合其他药物治疗非小细胞肺癌患者

Abemaciclib是细胞周期蛋白依赖性激酶4和6的双重抑制剂,已在非小细胞肺癌(NSCLC)中显示出临床前活性。CLIN CANCER RES近期发表了一篇文章,报道了一项多中心,非随机, Ib期临床试验结果,该试验研究了abemaciclib治疗转移性NSCLC患者的安全性,MTD,药代动力学和初步的抗肿瘤活性。

PLos One:肿瘤周围放射学特征可以预测局部晚期NSCLC的远处转移

这项研究确定了与DM显著相关的肿瘤周围边缘放射学特征。

Chest:I-IIIa期非小细胞肺癌临床分期的准确性

该研究表明临床和病理分期之间的一致性欠佳。

NEJM:非小细胞肺癌的粟粒样转移-病例报道

该患者开始接受厄洛替尼治疗,并进行后路脊柱融合和减压手术。1年后,患者对厄洛替尼治疗有部分反应;没有接受吸氧治疗,也不会出现呼吸急促。

NCCN临床实践指南:非小细胞肺癌(2019.V1)

2018年10月,美国国家综合癌症网络(NCCN)发布了非小细胞肺癌指南2019年第1版,指南较前一版有较大程度改动,主要内容涉及: 指南更新摘要 肺癌的预防和筛查 肺癌的临床表现和风险评估 初始评估和临床分期 各期肺癌的评估和治疗 完成确定治疗后监测 复发和转移性疾病的治疗 转移性疾病的系统治疗 病理检查原则 手术治疗原则 放射治疗原则 新辅助化疗方案与辅助治疗 放射治疗和化疗 晚期或转移性疾病

Baidu
map
Baidu
map
Baidu
map